[1]黄少辉,李 渊,李淑婧,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白逐步减量维持治疗强直性脊柱炎的效果[J].医学信息,2021,34(02):152-154.[doi:10.3969/j.issn.1006-1959.2021.02.042]
　HUANG Shao-hui,LI Yuan,LI Shu-jing,et al.Effect of Recombinant Human Type II Tumor Necrosis Factor Receptor-antibody Fusion Protein Reduction on the Treatment of Ankylosing Spondylitis[J].Medical Information,2021,34(02):152-154.[doi:10.3969/j.issn.1006-1959.2021.02.042]
点击复制

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白逐步减量维持治疗强直性脊柱炎的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年02期
页码:
152-154
栏目:
药物与临床
出版日期:
2021-01-15

文章信息/Info

Title:
Effect of Recombinant Human Type II Tumor Necrosis Factor Receptor-antibody Fusion Protein Reduction on the Treatment of Ankylosing Spondylitis
文章编号:
1006-1959（2021）02-0152-03
作者:
黄少辉; 李 渊; 李淑婧; 等
（武警甘肃总队医院特色专业一科1，外二科2，卫勤处3，药剂科4，甘肃 兰州 730050）
Author(s):
HUANG Shao-hui; LI Yuan; LI Shu-jing; et al.
(The First Department of Specialty1,the Second Department of Surgery2,Department of Health Service3,Department of Pharmacy4, Gansu General Corps Hospital of the Armed Police Force,Lanzhou 730050,Gansu,China)
关键词:
强直性脊柱炎; 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白; C反应蛋白
Keywords:
Ankylosing spondylitis; Recombinant human type II tumor necrosis factor receptor-antibody fusion protein; C reactive protein
分类号:
R593.23
DOI:
10.3969/j.issn.1006-1959.2021.02.042
文献标志码:
A
摘要:
目的 研究重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白标准治疗3个月后逐步降低给药频率维持治疗的疗效和安全性评价。方法 选取我院2015年6月~2019年6月收治的经标准治疗3个月的强直性脊柱炎患者46例作为研究对象，按照随机数字表法分为对照组和实验组，各23例。对照组给予25 mg皮下注射，2次/周，持续治疗6个月；实验组6个月内逐步将治疗间隔调整为每2周1次，比较两组治疗后ASAS20比例，炎症因子[C反应蛋白（CRP）、红细胞沉降率（ESR）]、活动度（BASDAI指数）和药物不良反应发生情况。结果 治疗3、6个月后，两组达到ASAS20占比、CRP、ESR、BASDAI比较，差异无统计学意义（P＞0.05）；实验组不良反应发生率为10.26%，低于对照组的30.77%，但差异无统计学意义（P＞0.05）。结论 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白标准治疗后逐步延长给药间隔，可以持续改善临床症状，保持疾病低活动度，且不良反应较少。
Abstract:
Objective To study the efficacy and safety evaluation of the standard treatment of recombinant human tumor necrosis factor receptor-antibody fusion protein 3 months after gradually reducing the frequency of administration.Methods A total of 46 patients with ankylosing spondylitis treated in our hospital from June 2015 to June 2019 who had undergone standard treatment for 3 months were selected as the research objects. According to the random number table, they were divided into control group and experimental group, with 23 cases in each group.The control group was given 25 mg subcutaneous injection twice a week for 6 months of continuous treatment;The experimental group gradually adjusted the treatment interval to once every 2 weeks within 6 months, and compared the ratio of ASAS20, inflammatory factors [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)], and activity (BASDAI index) between the two groups after treatment. And the occurrence of adverse drug reactions.Results After 3 and 6 months of treatment, there was no statistically significant difference between the two groups in the proportion of ASAS20, CRP, ESR, and BASDAI (P>0.05);The incidence of adverse reactions in the experimental group was 10.26%, which was lower than 30.77% in the control group, but the difference was not statistically significant (P>0.05).Conclusion Prolonging the interval of administration after standard treatment of recombinant human type II tumor necrosis factor receptor-antibody fusion protein can continuously improve clinical symptoms, maintain low activity of disease, and have less adverse reactions.

参考文献/References:

[1]陈桃,王天,蔡琪,许家健.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎疗效及对血清MK和Th17/Terg的影响[J].河北医药,2019,41(9):1352-1355. [2]中华医学会风湿病学分会.强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010(8):557-559. [3]艾星,张杰,王朝云,等.阿达木单抗注射液生物类似药临床试验设计考虑要点[J].中国临床药理学杂志,2019,35(23):3167-3171. [4]路峰.ASDAS、RAPID3及BASDAI病情活动性指标判断强直性脊柱炎患者活动度效果比较研究[J].中国实用医药,2017,12(32):68-69. [5]陈俊岚,周时高.强直性脊柱炎相关细胞因子的研究进展[J].江西中医药,2019,50(439):64-68. [6]蔡慧颜,钟华.强直性脊柱炎患者外周血TNF-α、IL-17、IL-23的表达[J].现代诊断与治疗,2016,27(18):3340-3342. [7]谢建丽,陈海英,王俊祥,等.超声评价抗肿瘤坏死因子α制剂对强直性脊柱炎跟腱附着点炎的疗效[J].临床荟萃,2018(5):431-433,439. [8]王星,张莹,郑军,等.TNF-α拮抗剂治疗早期强直性脊柱炎临床效果观察[J].西南国防医药,2019(12):1200-1203. [9]高丽红,刘欣,吴歆,等.Wnt/β-catenin信号通路在强直性脊柱炎成骨中的研究进展[J].第二军医大学学报,2019,40(4):435-439. [10]Feng W,Guo J,Li M.RANKL-independent modulation of osteoclastogenesis[J].J Oral Biosci,2019,61(1):16-21. [11]Davis JC Jr,van der Heijde DM,Braun J,et al.Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis[J].Ann Rheum Dis,2008,67(3):346-352. [12]Verhoef LM,van den Bemt BJ,van der Maas A,et al.Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity[J].Cochrane Database Syst Rev,2019,5(5):CD010455. [13]Arends S,van der Veer E,Kamps FB,et al.Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice[J].Clin Exp Rheumatol,2015,33(2):174-180. [14]余海燕.注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白剂量递减方案与标准剂量维持方案治疗强直性脊柱炎的疗效比较[J].广州医药,2019,50(1):12-15. [15]杨娉婷,赵丽娟,肖卫国.强直性脊柱炎患者益赛普减量经验——为期1年的开放式前瞻性临床研究结果[J].中国医科大学学报,2011,40(1):57-59,63. [16]宋颖钰,崔阳,张晓,等.肿瘤坏死因子抑制剂减量维持治疗脊柱关节炎患者关节病变的初步研究[J].中华风湿病学杂志,2017,21(11):724-731. [17]王苏丽,刘维超,宋洋,等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白剂量递减方案治疗强直性脊柱炎的临床疗效观察[J].中华风湿病学杂志,2016,20(11):746-749.

相似文献/References:

[1]朱晓波,常 泰.强直性脊柱炎髋关节受累磁共振横断面扫描与 冠状面扫描的对比分析[J].医学信息,2018,31(16):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
　ZHU Xiao-bo,CHANG Tai.Comparative Analysis of Magnetic Resonance Cross-sectional Scan and Coronal Scan in Hip Joint of Ankylosing Spondylitis[J].Medical Information,2018,31(02):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
[2]张 伟.艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效[J].医学信息,2022,35(15):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]
　ZHANG Wei.Efficacy of Iguratimod Combined with Celecoxib in the Treatment of Ankylosing Spondylitis[J].Medical Information,2022,35(02):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]
[3]刘军莲,戴 娜,杨 迎,等.全脊柱MRI对强直性脊柱炎急性炎症的诊断价值[J].医学信息,2019,32(16):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
　LIU Jun-lian,DAI Na,YANG Ying,et al.Diagnostic Value of Total Spine MRI in Acute Inflammation of Ankylosing Spondylitis[J].Medical Information,2019,32(02):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
[4]翁於欢,王璐颖,郑 勇,等.强直性脊柱炎中医证候分布研究[J].医学信息,2020,33(01):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
　WENG Yu-huan,WANG Lu-ying,ZHENG Yong,et al.Study on TCM Syndrome Distribution of Ankylosing Spondylitis[J].Medical Information,2020,33(02):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
[5]陈王曼琍,施春香.Orem自理理论护理对中西医结合治疗强直性脊柱炎的疗效研究[J].医学信息,2020,33(11):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
　CHEN Man-li,SHI Chun-xiang.Study on the Curative Effect of Orem Self-care Theory Nursing Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine[J].Medical Information,2020,33(02):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
[6]薛三宝.MRI诊断强直性脊柱炎骶髂关节病变的影像学价值[J].医学信息,2022,35(22):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]
　XUE San-bao.Imaging Value of MRI in Diagnosis of Sacroiliac Joint Lesions in Ankylosing Spondylitis[J].Medical Information,2022,35(02):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]

更新日期/Last Update: 1900-01-01